NASDAQ:EBACU

European Biotech Acquisition Corp. Units Stock Forecast, Price & News

$10.10
-0.05 (-0.49 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.10
Now: $10.10
$10.15
50-Day Range N/A
52-Week Range
$9.77
Now: $10.10
$10.32
Volume6,813 shs
Average Volume136,664 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for European Biotech Acquisition Corp.

Industry, Sector and Symbol

Industry --
Sub-IndustryN/A
Sector--
Current SymbolNASDAQ:EBACU
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

-- Sector

220th out of 266 stocks

-- Industry

222nd out of 268 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$10.10
-0.05 (-0.49 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EBACU News and Ratings via Email

Sign-up to receive the latest news and ratings for EBACU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











European Biotech Acquisition Corp. Units (NASDAQ:EBACU) Frequently Asked Questions

What stocks does MarketBeat like better than European Biotech Acquisition Corp. Units?

Wall Street analysts have given European Biotech Acquisition Corp. Units a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but European Biotech Acquisition Corp. Units wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of European Biotech Acquisition Corp. Units' key competitors?

When did European Biotech Acquisition Corp. Units IPO?

(EBACU) raised $100 million in an initial public offering on Tuesday, March 16th 2021. The company issued 10,000,000 shares at a price of $10.00 per share. Credit Suisse and Kempen & Co. served as the underwriters for the IPO.

What is European Biotech Acquisition Corp. Units' stock symbol?

European Biotech Acquisition Corp. Units trades on the NASDAQ under the ticker symbol "EBACU."

When does the company's quiet period expire?

European Biotech Acquisition Corp. Units' quiet period expires on Monday, April 26th. European Biotech Acquisition Corp. Units had issued 12,000,000 shares in its public offering on March 16th. The total size of the offering was $120,000,000 based on an initial share price of $10.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of European Biotech Acquisition Corp. Units?

Shares of EBACU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is European Biotech Acquisition Corp. Units' stock price today?

One share of EBACU stock can currently be purchased for approximately $10.10.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.